The latest biotech news

News and Trends 8 Mar 2018

French Biotech Targets Gut Microbiome to Treat Diabetes

Valbiotis has shown that its treatment restores diversity in a population of gut microorganisms imbalanced by type 2 diabetes in mice. Valbiotis, based in Périgny, France, wants to treat type 2 diabetes by restoring the balance of microbial populations in the gut microbiome. New data from a metagenomic sequencing study in mice has shown that its drug, […]

March 8, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 7 Mar 2018

This Spanish Biotech Might Have the First Effective Treatment for a Rare Blood Condition

Sanifit has successfully completed a Phase II trial with what could be the first effective treatment for calciphylaxis, a deadly rare disease caused by calcium accumulation in the blood. Mallorca-based Sanifit is targeting calciphylaxis with its treatment called SNF472. Results from Sanifit’s Phase II trial show that the drug promotes wound healing and reduces pain, though the details […]

March 7, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 7 Mar 2018

Oxford Keeps Growing as a Hotspot for Cancer Vaccines with New Fundraising

Oxford Vacmedix has secured $12.5M (€10M) to start its first clinical trials, joining other Oxford-based biotechs in the cancer vaccine field such as Vaccitech and SpyBiotech. Oxford Vacmedix has secured Series A financing to continue the development of its two lead cancer vaccines to target cervical cancer and other solid tumors. The financing round represents the […]

March 7, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 6 Mar 2018

Oxford Spin-out Moves Gene Therapy For Blindness Into Phase III Trial

Nightstar Therapeutics will begin the first Phase III trial for a gene therapy targeting choroideremia, a rare disorder leading to complete blindness. Nightstar will launch the first-ever Phase III trial testing a gene therapy for choroideremia, a genetic disorder characterized by night blindness and gradual loss of vision that eventually leads to complete blindness. The trial, STAR, […]

March 6, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 6 Mar 2018

Swiss VC Closes €86M Fund for Medical Biotech in Europe

BioMedPartners has raised CHF100M (€86M) that will be invested in medical biotech companies in Switzerland, Germany, and other EU countries. Swiss VC BioMedPartners has managed to gather some big European investors to close its third venture capital fund, called BioMedInvest III and sized at CHF 100M (€86M). Among the investors are the European Investment Fund […]

March 6, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Mar 2018

French Biotech Uses Natural Peptides to Boost Plant Growth and Immunity

Micropep Technologies, a Toulouse-based biotech, has raised €4M to develop peptides that boost plant growth and disease resistance by regulating gene expression. Micropep Technologies has raised a Series A funding with the support of two new investors, Sofinnova Partners, the largest industrial biotech fund in the world, and Irdi Soridec Gestion. The company aims to use the funding […]

March 6, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 5 Mar 2018

Danish Biotech Starts Phase III Atopic Dermatitis Trial With Failed Asthma Treatment

Danish biotech LEO Pharma started a Phase III trial in atopic dermatitis with an antibody that AstraZeneca dropped after failing two Phase III trials in asthma. LEO Pharma is taking over the development of the antibody tralokinumab from AstraZeneca to treat atopic dermatitis after the drug failed multiple Phase III studies for treating asthma. In […]

March 5, 2018 - 2 minutesmins - By Alexander Burik

santhera multiple sclerosis trial idebenone

News and Trends 5 Mar 2018

Swiss Company Hits Another Slump with a Failed Multiple Sclerosis Trial

Just months after the EMA rejected its therapy for Duchenne muscular dystrophy, Swiss company Santhera reports negative data for its multiple sclerosis drug. Santhera Pharmaceuticals has reported this morning that a first clinical trial in patients with primary progressive multiple sclerosis (PPMS) failed to prove the company’s drug to have any effect on the progression of […]

March 5, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 2 Mar 2018

London Biotech Uses Unique Double Mechanism of Action to Treat Cystic Fibrosis

Verona Pharma obtained positive Phase IIa trial results for a unique cystic fibrosis drug that inhibits two disease-related enzymes simultaneously, showing promise for treating a high unmet patient need. Verona Pharma, based in London, UK, aims to improve the lives of people with chronic respiratory diseases. Verona states their Phase IIa data provide grounds to […]

March 2, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 1 Mar 2018

Biosensors Bring HIV Test to Patients for Instant Results

A report on the use of biosensors in molecular disease diagnostics states the technology could significantly reduce the spread of HIV. A report by Cambridge-based IDTechEx analyzed important trends in the field of medical biosensors. Their results suggest the technology could reduce the spread of HIV and sexually transmitted diseases in general by cutting the time taken to send tests to a […]

March 1, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 1 Mar 2018

Doudna and Charpentier Get Second CRISPR Patent in Europe

Just a month after the European Patent Office revoked a CRISPR patent from the competitors of Doudna and Charpentier, they have been granted a second patent that covers a new form of the popular gene editing tool. The European Patent Office has granted CRISPR co-inventor Emmanuelle Charpentier, together with the University of California and the University […]

March 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Mar 2018

Could This Parisian Biotech Startup’s Cancer Treatment Compete With Merck and Novartis?

Stimunity, a Parisian biotech, secured a 2M€ seed investment to develop a cancer treatment that could compete with that of big players such as Merck and Novartis. Stimunity is a preclinical-stage startup company which develops drugs targeting a new cell signalling pathway to treat cancer. The company secured funding from Portage, a US-Canadian firm that […]

March 1, 2018 - 3 minutesmins - By Alexander Burik

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

French Biotech Targets Gut Microbiome to Treat Diabetes

This Spanish Biotech Might Have the First Effective Treatment for a Rare Blood Condition

Oxford Keeps Growing as a Hotspot for Cancer Vaccines with New Fundraising

Oxford Spin-out Moves Gene Therapy For Blindness Into Phase III Trial

Swiss VC Closes €86M Fund for Medical Biotech in Europe

French Biotech Uses Natural Peptides to Boost Plant Growth and Immunity

Danish Biotech Starts Phase III Atopic Dermatitis Trial With Failed Asthma Treatment

Swiss Company Hits Another Slump with a Failed Multiple Sclerosis Trial

London Biotech Uses Unique Double Mechanism of Action to Treat Cystic Fibrosis

Biosensors Bring HIV Test to Patients for Instant Results

Doudna and Charpentier Get Second CRISPR Patent in Europe

Could This Parisian Biotech Startup’s Cancer Treatment Compete With Merck and Novartis?

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!